Abstract
Synthetic mRNA has been considered as an emerging biotherapeutic agent for the past decades. Recently, the SARS-CoV-2 pandemic has led to the first clinical use of synthetic mRNA. mRNA vaccines showed far surpassing influences on the public as compared to other vaccine platforms such as viral vector vaccines and recombinant protein vaccines. It allowed rapid development and production of vaccines that have never been achieved in history. Synthetic mRNA, called in vitro transcribed (IVT) mRNA, is the key component of mRNA vaccines. It has several advantages over conventional gene-expressing systems such as plasmid DNA and viral vectors. It can translate proteins in the cytoplasm by structurally resembling natural mRNA and exhibit various protein expression patterns depending on how it is engineered. Another advantage is that synthetic mRNA enables fast, scalable, and cost-effective production. Therefore, starting with the mRNA vaccine, synthetic mRNA is now in the spotlight as a promising new drug development agent. In this review, we will summarize the latest IVT mRNA technology such as new mRNA structures or large-scale production. In addition, the nature of the innate immunogenicity of IVT mRNA will be discussed along with its roles in the development of vaccines. Finally, the principles of the mRNA vaccine and the future direction of synthetic mRNA will be provided.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413(6857):732–738. https://doi.org/10.1038/35099560
Baden LR, El Sahly HM, Essink B, Kotloff K, Sharon Frey MD, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389
Baiersdörfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, Karikó K (2019) A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids 15:26–35. https://doi.org/10.1016/j.omtn.2019.02.018
Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2(2):112–120. https://doi.org/10.1158/2326-6066.CIR-13-0170
Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM (2021) mRNA therapeutics in cancer immunotherapy. Mol Cancer 20(1):69. https://doi.org/10.1186/s12943-021-01348-0
Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, Brill S, Haefner E, Becker R, Türeci Ö, Sahin U (2020) A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther 28(1):119–128. https://doi.org/10.1016/j.ymthe.2019.09.009
Binder M, Eberle F, Seitz S, Mücke N, Hüber CM, Kiani N, Kaderali L, Lohmann V, Dalpke A, Bartenschlager R (2011) Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem 286(31):27278–27287. https://doi.org/10.1074/jbc.M111.256974
Bloom K, van den Berg F, Arbuthnot P (2020) Self-amplifying RNA vaccines for infectious diseases. Gene Ther 28(3–4):117–129. https://doi.org/10.1038/s41434-020-00204-y
Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184(2):465–472. https://doi.org/10.1084/jem.184.2.465
Botos I, Liu L, Wang Y, Segal DM, Davies DR (2009) The toll-like receptor 3:dsRNA signaling complex. Biochem Biophys Acta 1789(9–10):667–674. https://doi.org/10.1016/j.bbagrm.2009.06.005
Brenner S, Jacob F, Meselson M (1961) An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190(4776):576–581. https://doi.org/10.1038/190576a0
Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, Verbeke R, Lentacker I, Thielemans K, Breckpot K (2016) Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon. Mol Ther Nucleic Acids 5:e326. https://doi.org/10.1038/mtna.2016.38
Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA (2020) mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Investig 130(11):5976–5988. https://doi.org/10.1172/JCI134915
Cannarozzi G, Schraudolph NN, Faty M, von Rohr P, Friberg MT, Roth AC, Gonnet P, Gonnet G, Barral Y (2010) A role for codon order in translation dynamics. Cell 141(2):355–367. https://doi.org/10.1016/j.cell.2010.02.036
Ceppi M, Ruggli N, Tache V, Gerber H, McCullough KC, Summerfield A (2005) Double-stranded secondary structures on mRNA induce type I interferon (IFN alpha/beta) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J Gene Med 7(4):452–465. https://doi.org/10.1002/jgm.685
Chaudhary N, Weissman D, Whitehead KA (2021) mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discovery. https://doi.org/10.1038/s41573-021-00283-5
Chen C-YA, Shyu A-B (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20(11):465–470. https://doi.org/10.1016/s0968-0004(00)89102-1
Chen L-L, Yang L (2015) Regulation of circRNA biogenesis. RNA Biol 12(4):381–388. https://doi.org/10.1080/15476286.2015.1020271
Chua KY, Kuo IC, Huang CH (2009) DNA vaccines for the prevention and treatment of allergy. Curr Opin Allergy Clin Immunol 9(1):50–54. https://doi.org/10.1097/ACI.0b013e3283207ad8
Clemens MJ, Elia A (1997) The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 17(9):503–524. https://doi.org/10.1016/S1357-2725(96)00169-0
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong W-P, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS (2020) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586(7830):567–571. https://doi.org/10.1038/s41586-020-2622-0
De Beuckelaer A, Grooten J, De Koker S (2017) Type I interferons modulate CD8 + T cell immunity to mRNA vaccines. Trends Mol Med 23(3):216–226. https://doi.org/10.1016/j.molmed.2017.01.006
Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663):1529–1531. https://doi.org/10.1126/science.1093616
Dimitriadis GJ (1978) Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274(5674):923–924. https://doi.org/10.1038/274923a0
Durbin AF, Wang C, Marcotrigiano J, Gehrke L (2016) RNAs containing modified nucleotides fail to trigger RIG-I conformational changes for innate immune signaling. mBio. https://doi.org/10.1128/mBio.00833-16
Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y (2015) Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res 44(3):1370–1383. https://doi.org/10.1093/nar/gkv1367
Fleeton MN, Chen M, Berglund P, Rhodes G, Parker SE, Murphy M, Atkins GJ, Liljeström P (2001) Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183(9):1395–1398. https://doi.org/10.1086/319857
Franklin RM (1966) Purification and properties of the replicative intermediate of the RNA bacteriophage R17. Proc Natl Acad Sci USA 55(6):1504–1511. https://doi.org/10.1073/pnas.55.6.1504
Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D, Krammer F, Coughlan L, Palese P, Pardi N, Nachbagauer R (2020) A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther J Am Soc Gene Ther 28(7):1569–1584. https://doi.org/10.1016/j.ymthe.2020.04.018
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31(9):822–826. https://doi.org/10.1038/nbt.2623
Furuichi Y, Miura K-I (1975) A blocked structure at the 5′ terminus of mRNA from cytoplasmic polyhedrosis virus. Nature 253(5490):374–375. https://doi.org/10.1038/253374a0
Gallie DR (1991) The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev 5(11):2108–2116. https://doi.org/10.1101/gad.5.11.2108
Gaspar P, Moura G, Santos MAS, Oliveira JL (2013) mRNA secondary structure optimization using a correlated stem–loop prediction. Nucleic Acids Res 41(6):e73–e73. https://doi.org/10.1093/nar/gks1473
Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci 109(36):14604–14609. https://doi.org/10.1073/pnas.1209367109
Gholamalipour Y, Karunanayake Mudiyanselage A, Martin CT (2018) 3′ end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in character-RNA-Seq analyses. Nucleic Acids Res 46(18):9253–9263. https://doi.org/10.1093/nar/gky796
Grier AE, Burleigh S, Sahni J, Clough CA, Cardot V, Choe DC, Krutein MC, Rawlings DJ, Jensen MC, Scharenberg AM, Jacoby K (2016) pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences. Mol Ther Nucleic Acids 5:e306. https://doi.org/10.1038/mtna.2016.21
Guo XR, Wang XL, Li MC, Yuan YH, Chen Y, Zou DD, Bian LJ, Li DS (2015) PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin Exp Med 15(4):501–509. https://doi.org/10.1007/s10238-014-0319-0
Gustafsson C, Govindarajan S, Minshull J (2004) Codon bias and heterologous protein expression. Trends Biotechnol 22(7):346–353. https://doi.org/10.1016/j.tibtech.2004.04.006
Hanson G, Coller J (2018) Codon optimality, bias and usage in translation and mRNA decay. Nat Rev Mol Cell Biol 19(1):20–30. https://doi.org/10.1038/nrm.2017.91
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663):1526–1529. https://doi.org/10.1126/science.1093620
Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi Z-Q, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microb Infect 2(1):1–7. https://doi.org/10.1038/emi.2013.54
Henderson JM, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N, McReynolds T, Cabral CR, Escamilla-Powers JR, Houston ME (2021) Cap 1 messenger RNA synthesis with co-transcriptional CleanCap® analog by in vitro transcription. Curr Protoc 1(2):e39. https://doi.org/10.1002/cpz1.39
Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17(9):2619–2627. https://doi.org/10.1158/1078-0432.CCR-10-1114
Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng X, Hinkley SJ, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29(8):731–734. https://doi.org/10.1038/nbt.1927
Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Türeci O, Sahin U (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108(13):4009–4017. https://doi.org/10.1182/blood-2006-04-015024
Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann K-K, Schlee M, Endres S, Hartmann G (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314(5801):994–997. https://doi.org/10.1126/science.1132505
Isaacs A, Cox RA, Rotem Z (1963) Foreign nucleic acids as the stimulus to make interferon. Lancet 282(7299):113–116. https://doi.org/10.1016/s0140-6736(63)92585-6
Jain R, Frederick JP, Huang EY, Burke KE, Mauger DM, Andrianova EA, Farlow SJ, Siddiqui S, Pimentel J, Cheung-Ong K, McKinney KM, Köhrer C, Moore MJ, Chakraborty T (2018) MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct. Nucleic Acid Ther 28(5):285–296. https://doi.org/10.1089/nat.2018.0734
Jeck WR, Sharpless NE (2014) Detecting and characterizing circular RNAs. Nat Biotechnol 32(5):453–461. https://doi.org/10.1038/nbt.2890
Jemielity J (2003) Novel “anti-reverse” cap analogs with superior translational properties. RNA 9(9):1108–1122. https://doi.org/10.1261/rna.5430403
Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE (1992) Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255(5047):996–998. https://doi.org/10.1126/science.1546298
Karikó K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2):165–175. https://doi.org/10.1016/j.immuni.2005.06.008
Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther J Am Soc Gene Ther 16(11):1833–1840. https://doi.org/10.1038/mt.2008.200
Karikó K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39(21):e142–e142. https://doi.org/10.1093/nar/gkr695
Karikó K, Muramatsu H, Keller JM, Weissman D (2012) Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther J Am Soc Gene Ther 20(5):948–953. https://doi.org/10.1038/mt.2012.7
Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, Dermody TS, Fujita T, Akira S (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205(7):1601–1610. https://doi.org/10.1084/jem.20080091
Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “Silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811):525–528. https://doi.org/10.1126/science.1135308
Kozak M (1986) Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc Natl Acad Sci 83(9):2850–2854. https://doi.org/10.1073/pnas.83.9.2850
Kumar P, Sweeney TR, Skabkin MA, Skabkina OV, Hellen CU, Pestova TV (2014) Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5′-terminal regions of cap0-, cap1- and 5′ppp- mRNAs. Nucleic Acids Res 42(5):3228–3245. https://doi.org/10.1093/nar/gkt1321
Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH 3rd, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tombácz I, Arwood L, Nachbagauer R, Karikó K, Grrenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, Lin PJC, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Anderson H, Eisenlonhr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N (2020) A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53(4):724-732.e7. https://doi.org/10.1016/j.immuni.2020.07.019
Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade M, Laneve P, Rajewsky N, Bozzoni I (2017) Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell 66(1):22-37.e9. https://doi.org/10.1016/j.molcel.2017.02.017
Lima SA, Chipman LB, Nicholson AL, Chen Y-H, Yee BA, Yeo GW, Coller J, Pasquinelli AE (2017) Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol 24(12):1057–1063. https://doi.org/10.1038/nsmb.3499
Lin L, Cho S-F, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai Y-T (2021) Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35(3):752–763. https://doi.org/10.1038/s41375-020-0951-5
Linares-Fernández S, Lacroix C, Exposito JY, Verrier B (2020) Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med 26(3):311–323. https://doi.org/10.1016/j.molmed.2019.10.002
Linares-Fernández S, Moreno J, Lambert E, Mercier-Gouy P, Vachez L, Verrier B, Exposito J-Y (2021) Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA. Mol Ther Nucleic Acids 26:945–956. https://doi.org/10.1016/j.omtn.2021.10.007
Loomis KH, Lindsay KE, Zurla C, Bhosle SM, Vanover DA, Blanchard EL, Kirschman JL, Bellamkonda RV, Santangelo PJ (2018) In vitro transcribed mRNA vaccines with programmable stimulation of innate immunity. Bioconjug Chem 29(9):3072–3083. https://doi.org/10.1021/acs.bioconjchem.8b00443
Lundstrom K (2018) Self-replicating RNA viruses for RNA therapeutics. Molecules 23(12):3310. https://doi.org/10.3390/molecules23123310
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823–826. https://doi.org/10.1126/science.1232033
Malone RW, Felgner PL, Verma IM (1989) Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 86(16):6077–6081. https://doi.org/10.1073/pnas.86.16.6077
Martin SA, Paoletti E, Moss B (1975) Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem 250(24):9322–9329. https://doi.org/10.1016/s0021-9258(19)40646-7
Mauro VP, Chappell SA (2014) A critical analysis of codon optimization in human therapeutics. Trends Mol Med 20(11):604–613. https://doi.org/10.1016/j.molmed.2014.09.003
McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, Zhou J, Bouton CR, Rogers P, Polra K, Lin PJC, Barbosa C, Tam YK, Barclay WS, Shattock RJ (2020) Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. https://doi.org/10.1038/s41467-020-17409-9
Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, Shi Y, Sadtler K, Gao W, Lin J, Doloff JC, Langer R, Anderson DG (2019) Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol 37(10):1174–1185. https://doi.org/10.1038/s41587-019-0247-3
Miller JC, Holmes MC, Wang J, Guschin DY, Lee Y-L, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ (2007) An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25(7):778–785. https://doi.org/10.1038/nbt1319
Mockey M, Gonçalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P (2006) mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 340(4):1062–1068. https://doi.org/10.1016/j.bbrc.2005.12.105
Mu X, Greenwald E, Ahmad S, Hur S (2018) An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res 46(10):5239–5249. https://doi.org/10.1093/nar/gky177
Muthukrishnan S, Both GW, Furuichi Y, Shatkin AJ (1975) 5′-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation. Nature 255(5503):33–37. https://doi.org/10.1038/255033a0
Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156(4):836–843. https://doi.org/10.1016/j.cell.2014.01.027
Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Löwer M, Vallazza B, Beissert T, Bukur V, Kuhn AN, Türeci Ö, Sahin U (2019) Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening. Mol Ther 27(4):824–836. https://doi.org/10.1016/j.ymthe.2018.12.011
Ouranidis A, Davidopoulou C, Tashi R-K, Kachrimanis K (2021) Pharma 4.0 continuous mRNA drug products manufacturing. Pharmaceutics 13(9):1371. https://doi.org/10.3390/pharmaceutics13091371
Pantel A, Teixeira A, Haddad E, Wood EG, Steinman RM, Longhi MP (2014) Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol 12(1):e1001759. https://doi.org/10.1371/journal.pbio.1001759
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TM, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248–251. https://doi.org/10.1038/nature21428
Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discovery 17(4):261–279. https://doi.org/10.1038/nrd.2017.243
Pelletier J, Sonenberg N (1985) Insertion mutagenesis to increase secondary structure within the 5′ noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell 40(3):515–526. https://doi.org/10.1016/0092-8674(85)90200-4
Perez CR, De Palma M (2019) Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. https://doi.org/10.1038/s41467-019-13368-y
Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, Romero RE, Tang Z, Bin Q, Dubensky TW, Vajdy M, Otten GR, Polo JM (2003) An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77(19):10394–10403. https://doi.org/10.1128/jvi.77.19.10394-10403.200
Petkovic S, Müller S (2015) RNA circularization strategies in vivo and in vitro. Nucleic Acids Res 43(4):2454–2465. https://doi.org/10.1093/nar/gkv045
Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen K-J, Stitz L, Kramps T (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30(12):1210–1216. https://doi.org/10.1038/nbt.2436
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577
Preskey D, Allison TF, Jones M, Mamchaoui K, Unger C (2016) Synthetically modified mRNA for efficient and fast human iPS cell generation and direct transdifferentiation to myoblasts. Biochem Biophys Res Commun 473(3):743–751. https://doi.org/10.1016/j.bbrc.2015.09.102
Pulit-Penaloza JA, Scherbik SV, Brinton MA (2012) Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation. Virology 425(2):71–81. https://doi.org/10.1016/j.virol.2011.11.025
Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, Weissman SM (2006) Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 17(10):1027–1035. https://doi.org/10.1089/hum.2006.17.1027
Rayner JO, Dryga SA, Kamrud KI (2002) Alphavirus vectors and vaccination. Rev Med Virol 12(5):279–296. https://doi.org/10.1002/rmv.360
Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA (1996) Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 93(10):5141–5145. https://doi.org/10.1073/pnas.93.10.5141
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS (2017) Modified mRNA vaccines protect against zika virus infection. Cell 168(6):1114-1125.e10. https://doi.org/10.1016/j.cell.2017.02.017
Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostböck S, Ferreira F, Thalhamer J, Scheiblhofer S (2009) Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 124(5):1070–7.e11. https://doi.org/10.1016/j.jaci.2009.06.036
Rosa SS, Prazeres D, Azevedo AM, Marques M (2021) mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39(16):2190–2200. https://doi.org/10.1016/j.vaccine.2021.03.038
Ross J, Sullivan T (1985) Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood 66(5):1149–1154. https://doi.org/10.1182/blood.V66.5.1149.1149
Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discovery 13(10):759–780. https://doi.org/10.1038/nrd4278
Sample PJ, Wang B, Reid DW, Presnyak V, McFadyen IJ, Morris DR, Seelig G (2019) Human 5′ UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol 37(7):803–809. https://doi.org/10.1038/s41587-019-0164-5
Scheiblhofer S, Thalhamer J, Weiss R (2018) DNA and mRNA vaccination against allergies. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol 29(7):679–688. https://doi.org/10.1111/pai.12964
Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, Juranek S, Kato H, Kawai T, Poeck H, Fitzgerald KA, Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J, Hartmann G (2009) Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31(1):25–34. https://doi.org/10.1016/j.immuni.2009.05.008
Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, Zhang X, Zhang P, Huang X (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23(5):720–723. https://doi.org/10.1038/cr.2013.46
Slater JE, Paupore E, Zhang YT, Colberg-Poley AM (1998) The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol 102(3):469–475. https://doi.org/10.1016/s0091-6749(98)70137-x
Spencer PS, Siller E, Anderson JF, Barral JM (2012) Silent substitutions predictably alter translation elongation rates and protein folding efficiencies. J Mol Biol 422(3):328–335. https://doi.org/10.1016/j.jmb.2012.06.010
Su X, Comeau AM (1999) Cellulose as a matrix for nucleic acid purification. Anal Biochem 267(2):415–418. https://doi.org/10.1006/abio.1998.2987
Sumiyama K, Kawakami K, Yagita K (2010) A simple and highly efficient transgenesis method in mice with the Tol2 transposon system and cytoplasmic microinjection. Genomics 95(5):306–311. https://doi.org/10.1016/j.ygeno.2010.02.006
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. https://doi.org/10.1016/j.cell.2006.07.024
Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH (2017) Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 5(12):1152–1161. https://doi.org/10.1158/2326-6066.CIR-17-0189
Triana-Alonso FJ, Dabrowski M, Wadzack J, Nierhaus KH (1995) Self-coded 3′-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J Biol Chem 270(11):6298–6307. https://doi.org/10.1074/jbc.270.11.6298
Uchida S, Yoshinaga N, Yanagihara K, Yuba E, Kataoka K, Itaka K (2018) Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination. Biomaterials 150:162–170. https://doi.org/10.1016/j.biomaterials.2017.09.033
Urayama S, Yoshida-Takashima Y, Yoshida M, Tomaru Y, Moriyama H, Takai K, Nunoura T (2015) A new fractionation and recovery method of viral genomes based on nucleic acid composition and structure using tandem column chromatography. Microbes Environ 30(2):199–203. https://doi.org/10.1264/jsme2.ME14174
Vaidyanathan S, Azizian KT, Haque A, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann M, Porteus MH, McCaffrey AP (2018) Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids 12:530–542. https://doi.org/10.1016/j.omtn.2018.06.010
Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, Vrtala S (2010) From allergen genes to allergy vaccines. Annu Rev Immunol 28:211–241. https://doi.org/10.1146/annurev-immunol-030409-101218
Verbeke R, Lentacker I, Wayteck L, Breckpot K, Van Bockstal M, Descamps B, Vanhove C, De Smedt SC, Dewitte H (2017) Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA. J Control Release 266:287–300. https://doi.org/10.1016/j.jconrel.2017.09.041
Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H, Reece ST, Sahin U, Tregoning JS (2018) Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther 26(2):446–455. https://doi.org/10.1016/j.ymthe.2017.11.017
Wang Y, Wang Z (2014) Efficient backsplicing produces translatable circular mRNAs. RNA 21(2):172–179. https://doi.org/10.1261/rna.048272.114
Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7(5):618–630. https://doi.org/10.1016/j.stem.2010.08.012
Wefers B, Panda SK, Ortiz O, Brandl C, Hensler S, Hansen J, Wurst W, Kühn R (2013) Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA. Nat Protoc 8(12):2355–2379. https://doi.org/10.1038/nprot.2013.142
Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J (2010) Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol 10(6):567–574. https://doi.org/10.1097/ACI.0b013e32833fd5b6
Weiss R, Scheiblhofer S, Roesler E, Weinberger E, Thalhamer J (2012) mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 11(1):55–67. https://doi.org/10.1586/erv.11.168
Wesselhoeft RA, Kowalski PS, Anderson DG (2018) Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. https://doi.org/10.1038/s41467-018-05096-6
Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A, Felgner P (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949):1465–1468. https://doi.org/10.1126/science.1690918
Wu MZ, Asahara H, Tzertzinis G, Roy B (2020) Synthesis of low immunogenicity RNA with high-temperature in vitro transcription. RNA 26(3):345–360. https://doi.org/10.1261/rna.073858.119
Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, Jin Q, Su L, Liu X, Wang K, Yan G, Dong T, Wu S, Zhou P, Zhang J, Liang W, Ren J, Teng Y, Chen C, Xu XH (2019) Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther J Am Soc Gene Ther 27(6):1114–1125. https://doi.org/10.1016/j.ymthe.2019.03.011
Yang D, Xu J, Zhu T, Fan J, Lai L, Zhang J, Chen YE (2014) Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. J Mol Cell Biol 6(1):97–99. https://doi.org/10.1093/jmcb/mjt047
Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Später D, Xu H, Tabebordbar M, Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, Chien KR (2013) Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31(10):898–907. https://doi.org/10.1038/nbt.2682
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, Guo Y, Sun SH, Fan H, Zu SL, Chen Q, He Q, Cao TS, Huang XY, Qiu HY, Nie JH, Jiang Y, Yan HY, Ye Q, Zhong X, Xue XL, Zha ZY, Zhou D, Yang X, Wang YC, Ying B, Qin CF (2020) A thermostable mRNA vaccine against COVID-19. Cell 182(5):1271-1283.e16. https://doi.org/10.1016/j.cell.2020.07.024
Zhong Z, McCafferty S, Opsomer L, Wang H, Huysmans H, De Temmerman J, Lienenklaus S, Portela Catani JP, Combes F, Sanders NN (2021) Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs. Mol Ther J Am Soc Gene Ther 29(4):1370–1381. https://doi.org/10.1016/j.ymthe.2021.01.023
Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljeström P (1994) Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12(16):1510–1514. https://doi.org/10.1016/0264-410x(94)90074-4
Acknowledgements
This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Basic Science Research Program [2020R1A2C2004364], MRC Program [2018R1A5A2025286], and Biomedical Technology Development Program [2019M3A9H1103786]. Suji Kwon is grateful for financial support from the Hyundai Motor Chung Mong-Koo Foundation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kwon, S., Kwon, M., Im, S. et al. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch. Pharm. Res. 45, 245–262 (2022). https://doi.org/10.1007/s12272-022-01381-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-022-01381-7